Par Drugs (India) Buy Hold or Sell Recommendation
| PAR Stock | 294.05 12.65 4.50% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Par Drugs And is 'Strong Sell'. Macroaxis provides Par Drugs buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PAR positions.
Check out Par Drugs Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Par and provide practical buy, sell, or hold advice based on investors' constraints. Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Par |
Execute Par Drugs Buy or Sell Advice
The Par recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Par Drugs And. Macroaxis does not own or have any residual interests in Par Drugs And or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Par Drugs' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Par Drugs Trading Alerts and Improvement Suggestions
| Par Drugs And had very high historical volatility over the last 90 days | |
| Par Drugs And is unlikely to experience financial distress in the next 2 years | |
| Latest headline from news.google.com: Breakout stocks to buy or sell FSL to Indian Bank Sumeet Bagadia recommends five shares to buy today Stock Market News - Mint |
Par Drugs Returns Distribution Density
The distribution of Par Drugs' historical returns is an attempt to chart the uncertainty of Par Drugs' future price movements. The chart of the probability distribution of Par Drugs daily returns describes the distribution of returns around its average expected value. We use Par Drugs And price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Par Drugs returns is essential to provide solid investment advice for Par Drugs.
| Mean Return | 0.38 | Value At Risk | -4.19 | Potential Upside | 8.13 | Standard Deviation | 4.00 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Par Drugs historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Par Drugs Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 13.8M | (799.1K) | (17.2M) | (6.7M) | 12.0M | 12.6M | |
| Change In Cash | 73.5M | 137.8M | (49.6M) | 60.4M | 144.1M | 151.3M | |
| Free Cash Flow | 61.3M | 70.4M | 44.1M | 57.4M | 141.7M | 76.0M | |
| Depreciation | 27.6M | 28.2M | 32.8M | 32.3M | 34.4M | 33.2M | |
| Other Non Cash Items | (2.1M) | (51.2M) | (29.4M) | (44.7M) | 3.1M | 3.2M | |
| Capital Expenditures | 15.6M | 50.5M | 32.0M | 76.3M | 60.8M | 32.4M | |
| Net Income | 59.9M | 147.3M | 127.0M | 150.8M | 145.0M | 88.5M | |
| End Period Cash Flow | 73.8M | 211.6M | 162.1M | 222.4M | 366.5M | 384.9M | |
| Net Borrowings | (73.3M) | (57.3M) | 30.2M | (76.4M) | (68.8M) | (65.3M) | |
| Change To Netincome | 13.5M | 10.2M | (20.1M) | 5.4M | 4.9M | 5.6M |
Par Drugs Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Par Drugs or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Par Drugs' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Par stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.38 | |
β | Beta against Dow Jones | -0.02 | |
σ | Overall volatility | 4.05 | |
Ir | Information ratio | 0.06 |
Par Drugs Volatility Alert
Par Drugs And currently demonstrates below-average downside deviation. It has Information Ratio of 0.06 and Jensen Alpha of 0.38. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Par Drugs' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Par Drugs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Par Drugs Fundamentals Vs Peers
Comparing Par Drugs' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Par Drugs' direct or indirect competition across all of the common fundamentals between Par Drugs and the related equities. This way, we can detect undervalued stocks with similar characteristics as Par Drugs or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Par Drugs' fundamental indicators could also be used in its relative valuation, which is a method of valuing Par Drugs by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Par Drugs to competition |
| Fundamentals | Par Drugs | Peer Average |
| Return On Equity | 0.21 | -0.31 |
| Return On Asset | 0.14 | -0.14 |
| Profit Margin | 0.18 % | (1.27) % |
| Operating Margin | 0.30 % | (5.51) % |
| Current Valuation | 3.43 B | 16.62 B |
| Shares Outstanding | 12.3 M | 571.82 M |
| Price To Book | 3.74 X | 9.51 X |
| Price To Sales | 3.48 X | 11.42 X |
| Revenue | 956.4 M | 9.43 B |
| Gross Profit | 457.57 M | 27.38 B |
| EBITDA | 228.17 M | 3.9 B |
| Net Income | 145.01 M | 570.98 M |
| Total Debt | 159.79 M | 5.32 B |
| Book Value Per Share | 78.69 X | 1.93 K |
| Cash Flow From Operations | 202.49 M | 971.22 M |
| Earnings Per Share | 14.85 X | 3.12 X |
| Number Of Employees | 122 | 18.84 K |
| Beta | 0.15 | -0.15 |
| Market Capitalization | 3.62 B | 19.03 B |
| Total Asset | 1.02 B | 29.47 B |
| Retained Earnings | 625.51 M | 9.33 B |
| Working Capital | 471.85 M | 1.48 B |
| Net Asset | 1.02 B |
Par Drugs Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Par . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Par Drugs Buy or Sell Advice
When is the right time to buy or sell Par Drugs And? Buying financial instruments such as Par Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Par Drugs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Realty Funds Thematic Idea Now
Realty Funds
Funds or Etfs investing in real estate backed instruments or issues backed by different types of commercial properties. The Realty Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Realty Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Par Stock
Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.